Drug intelligence / Profile preview

TYME-19

Development stage: Preclinical
Lead developer: Tyme Technologies
Modality: Small Molecules
Administration: Oral

Overview

TYME-19 is an investigational oral synthetic bile acid derivative being developed by Tyme Technologies as a potential treatment for COVID-19. Preclinical data indicate broad-spectrum antiviral activity, with TYME-19 reducing SARS-CoV-2 viral replication in human lung epithelial cell models by interfering with the virus’s ability to hijack host cellular machinery.[1][12][3] The compound is related to a bile acid moiety also used in Tyme’s anticancer program TYME-18 and is positioned as a host-directed antiviral designed to be administered orally in early-stage or mild to moderate COVID-19 infections.[1][9][6]

Beyond the preview

Go deeper on TYME-19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TYME-19.

Explore the full profile